Are androgen receptor variants a substitute for the full-length receptor?

Ji Lu; Travis Van der Steen; Donald J Tindall

doi:10.1038/nrurol.2015.13

Are androgen receptor variants a substitute for the full-length receptor?

Nat Rev Urol. 2015 Mar;12(3):137-44. doi: 10.1038/nrurol.2015.13. Epub 2015 Feb 10.

Authors

Ji Lu¹, Travis Van der Steen², Donald J Tindall³

Affiliations

¹ Department of Urology, First Hospital of Jilin University, 71 Xinmin Street, Changchun 130021, China.
² Department of Urology, Mayo Clinic, 200 First Street SW Rochester, MN 55905, USA.
³ Department of Biochemistry and Molecular Biology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA.

PMID: 25666893
DOI: 10.1038/nrurol.2015.13

Abstract

Androgen receptor splice variants (AR-Vs)--which are expressed in castration-resistant prostate cancer (CRPC) cell lines and clinical samples--lack the C-terminal ligand-binding domain and are constitutively active. AR-Vs are, therefore, resistant to traditional androgen deprivation therapy (ADT). AR-Vs are induced by several mechanisms, including ADT, and might contribute to the progression of CRPC and resistance to ADT. AR-Vs could represent a novel therapeutic target for prostate cancer, especially in CRPC.

Publication types

Review

MeSH terms

Alternative Splicing
Animals
Disease Progression
Gene Expression Profiling
Gene Expression Regulation / physiology
Humans
Male
Neoplasms, Hormone-Dependent
Prostatic Neoplasms / drug therapy
Prostatic Neoplasms / genetics
Prostatic Neoplasms / metabolism*
Prostatic Neoplasms, Castration-Resistant / metabolism
Protein Isoforms
Receptors, Androgen / genetics
Receptors, Androgen / metabolism*
Signal Transduction / physiology

Substances

Protein Isoforms
Receptors, Androgen